Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Delta Hotels Ottawa City Centre

Oct 18, 2022 1:00 PM - Oct 19, 2022 9:10 PM

101 Lyon Street North, Ottawa, ON K1R 5T9, Canada

Canada Annual Meeting

Session 8, Track C: Vanessa's Law: Impact and Challenges of Mandatory Adverse Reaction Reporting

Session Chair(s)

Marcia  Bailey, BSN, MHS, RN

Marcia Bailey, BSN, MHS, RN

Safety Evaluation and Risk Management Scientific Director

GSK, Canada

Vanessa  Zapata

Vanessa Zapata

Associate Director, Regional Pharmacovigilance Officer

Merck Canada Inc., Canada

Vanessa’s Law (Bill C-17) became effective in 2014. This session provides an overview of Health Canada’s perspective and expectations regarding implementation of the law and its impact on health care facilities. This session will also include challenges that the pharmaceutical industry is currently facing.

Learning Objective : At the conclusion of this session, participants should be able to:
  • Explain Health Canada’s expectation regarding the implementation of Vanessa’s Law
  • Identify the actions required by health care facilities to be compliant with Vanessa’s Law
  • Describe challenges faced by the Industry following the implementation of Vanessa’s Law


Aurela  Balla, DrMed

Vanessa's Law: Impact and Challenges of Mandatory Adverse Reaction Reporting, from an Industry Perspective: Aurela Balla, DrMed

Senior Director, Pharmacovigilance

Merck Canada Inc., Canada

Marie-Claude  Brutus Lopez, RPh

Health Canada Refresher: Mandatory Reporting of Medical Device Incidents (MDIs) and Serious Adverse Drug Reactions (ADRs) by Hospitals: Marie-Claude Brutus Lopez, RPh

Coordinator, Canada Vigilance Program, Marketed Health Products Directorate

Health Canada, Canada

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.